SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending after securing a prime contract position in the U.S. Missile Defense Agency's SHIELD program, which is part of the Golden Dome strategy. The community is buzzing, interpreting this as a significant de-risking event that validates the company's unique dual-use satellite technology for both commercial and national security applications. This has fueled strong bullish sentiment, with many anticipating further upside driven by potential short covering.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following significantly raised revenue targets for fiscal years and a substantially increased backlog, alongside a strong cash position fueling acquisition speculation. The community is highly engaged, anticipating further positive updates from the upcoming Investor Day and noting increased pressure on short sellers. Speculation also circulates around a potential spin-off of its autonomous systems division, adding to the buzz.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is actively trending amid significant investments in AI infrastructure, highlighted by a new multi-billion dollar partnership with BlackRock for data centers and OpenAI's expanded compute collaboration with Cerebras. This comes as the stock experiences a notable dip, sparking widespread community debate over its "oversold" status and anticipation for its upcoming earnings report, particularly in the context of increasing AI data center energy costs and regulatory discussions.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials (RGNT), a recent IPO, is rapidly trending following significant patent news for its GelrinC product, already approved in Europe. The community is actively discussing its extremely low float of 1.25 million shares and 180-day insider lock-up, fueling speculation about a potential short squeeze. Many are highlighting the company's 

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending following significant ERCOT approval, which doubled its Helios data center's power capacity to over 1.6 gigawatts for AI-hosting. The community views this as a pivotal moment, anticipating a re-rating of Galaxy as a key AI infrastructure provider with substantial future growth potential beyond its traditional crypto business.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is surging amid reports of drastic price increases for its high-capacity 3D NAND and enterprise SSDs, fueled by explosive demand from the burgeoning AI infrastructure. This memory supercycle has propelled the stock to new highs, sparking a community debate between those who see it as an unstoppable market leader and others warning of an extreme valuation and potential bubble.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending with intense focus on its upcoming earnings report, as the community actively debates the implications of a potential all-cash offer for Warner Bros. Discovery assets and unconfirmed rumors of significant institutional buying. Investors are sharply divided, with some anticipating a substantial post-earnings rally from oversold levels, while others remain cautious due to acquisition-related uncertainties and recent stock performance. The market eagerly awaits clarity on both financial performance and the WBD deal's progression, driving high anticipation for the week ahead.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is generating significant buzz, driven by its unique optical interposer platform poised to revolutionize high-speed data transfer for AI and data centers. The community is actively discussing the recent acquisition of a key POET customer by a major semiconductor firm, which is widely seen as a strong validation of POET's underlying technology. This strategic move, coupled with expanding global partnerships, has ignited investor optimism for impending commercial milestones and robust order flow in the rapidly evolving photonics sector.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd is trending due to recent financial results indicating revenue growth in security-related engineering services and the anticipation of new contract news. The community is actively discussing its ultra-low share float and substantial short interest, leading to strong speculation about a potential short squeeze, drawing comparisons to other volatile 'Hong Kong low float' stocks.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is generating buzz with its recent USD1 payroll and card integration via World Liberty Finance, alongside anticipation for its Super App launch and expanded blockchain integrations. The community is actively discussing ZBCN's advanced ISO 20022 compliance and its strategic positioning within the real-world asset sector, frequently comparing its potential to established players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The U.K. medicines regulator stated that the maximum dose of 7.2 mg of Wegovy only applies to adult patients with a Body Mass Index (BMI) of 30kg/m² or higher.</li><li>As part of the approval, the regulator said that the drug is to be administered as three injections of 2.4 mg each, per week.</li><li>The approval is not applicable to patients with a BMI below 30kg/m² who use Wegovy for weight management, or to those who use the drug to reduce the risk of serious heart problems.</li></ul>Novo Nordisk AS (NVO) shares were up nearly 6% in Friday’s pre-market trade amid a new development in the company’s miracle weight loss drug, Wegovy.The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> was in the ‘bullish’ territory, with the stock being the top-trending ticker on the platform at the time of writing.<h2 class="st-heading-2">What Is The Wegovy Approval About?</h2>The U.K. medicines regulator stated that the maximum dose of 7.2 mg of Wegovy only applies to adult patients with a Body Mass Index (BMI) of 30kg/m² or higher.As part of the approval, the regulator said that the drug is to be administered as three injections of 2.4 mg each, per week.The approval is not applicable to patients with a BMI below 30kg/m² who use Wegovy for weight management, or to those who use the drug to reduce the risk of serious heart problems.The regulator also noted that patients who are starting Wegovy will have to begin with the 0.25 mg dose per week. Subsequently, with advice from a prescribed health professional, the dose can be increased to 7.2 mg per week after using the drug for a minimum of four weeks.<h2 class="st-heading-2">Boost From Wegovy Pill</h2>Earlier this month, Novo&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">announced</a> that patients in the U.S. can get the oral Wegovy pill starting at $149 a month.The company stated on its website that the 1.5 mg and 4 mg doses of Wegovy will be available to self-paying customers at these prices beginning January 5. However, the cost of the 4 mg dose will rise to $199 a month from April 15, 2026.Since the announcement, Novo shares are up nearly 4%. According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-13/novo-s-ceo-is-ready-to-go-very-big-in-hunt-for-obesity-deals">report</a>, the company is also said to be back on the hunt for obesity deals after losing out on Metsera Inc. to rival Pfizer Inc. (PFE) last year.<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Retail users on Stocktwits were bullish about Novo, with message volumes soaring nearly 50% over the last 24 hours.One bullish Stocktwits user believes that Novo has a “monopoly market” over the next three months.<stembedurl>https://stocktwits.com/kungfukenny___/message/642018122</stembedurl>However, one user expressed their dilemma, wondering whether the Greenland dispute could lead to a tariff increase on Denmark.<stembedurl>https://stocktwits.com/Ceri78/message/641994914</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is up 12% year-to-date, but down 31% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-loses-bid-fast-track-warner-bros-suit/cmU188XR4JP">Paramount Reportedly Loses Bid To Fast-Track Warner Bros Suit: PSKY Stock Edges Lower</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wegovy brand slimming syringes are sold in the Achat pharmacy in Mitte. Photo: Jens Kalaene/dpa (Photo by Jens Kalaene/picture alliance via Getty Images)

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares?

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

Equity

MGO One Seven LLC Has $1.39 Million Holdings in Novo Nordisk A/S $NVO

MGO One Seven LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 50.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities...

Novo Nordisk A/S (NYSE:NVO) Trading Down 3.1% - Here's What Happened

Novo Nordisk A/S (NYSE:NVO) Shares Down 3.1% - Should You Sell...

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit

Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.read more...

Top Pharmaceutical Stocks To Research - January 15th

Eli Lilly and Company, Novo Nordisk A/S, AbbVie, Pfizer, AstraZeneca, Abbott Laboratories, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Best Medical Stocks To Keep An Eye On - January 15th

Eli Lilly and Company, Penumbra, Boston Scientific, UnitedHealth Group, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?

Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.

Eagle Global Advisors LLC Trims Stake in Novo Nordisk A/S $NVO

Eagle Global Advisors LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.7% in the third quarter, according to the company in its most recent filing with the Securities...

<ul class="summary-bullets"><li>AbbVie CEO said that the company is now looking at candidates that provide sustained weight loss.&nbsp;</li><li>The obesity drug market is currently dominated by GLP-1 drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Ozempic.</li></ul>AbbVie (ABBV) chief executive officer Roopal Thakkar said on Wednesday that the company is looking to expand its obesity portfolio with candidates that help provide sustained weight loss.The obesity drug market is currently dominated by GLP-1 drugs such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Ozempic.Thakkar said at the annual JP Morgan Healthcare conference that key for AbbVie is tolerability and durability of weight loss for patients that tend to “cycle off of these first-gen therapies.”“Some of our data shows that only 30% or so patients are still taking these therapies after a year. So that's still, I would say, a critical aspect of our business development and licensing strategy,” Thakkar added.<h2 class="st-heading-2">Current Pipeline</h2>AbbVie already has a long-acting amylin analog for the treatment of obesity in its pipeline. A long-acting amylin analog is a drug designed to mimic the natural hormone amylin, which signals fullness and slows digestion, used for weight management in obesity and type 2 diabetes.AbbVie licensed the drug from Gubra A/S in March 2025, marking its entry into the obesity segment. The drug is currently in early stage trials."We have the longer acting amylin. We like the tolerability profile of that mechanism, but we are interested in building that out further," Thakkar said on Wednesday.AbbVie’s chief commercial officer Jeff Stewart also noted that the company wants to play in the “super dynamic” obesity market.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ABBV stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that AbbVie could become a big contender to Lilly with the right assets.<stembedurl>https://www.stocktwits.com/biolover/message/641825158</stembedurl><a href="https://stocktwits.com/symbol/ABBV">ABBV stock</a> gained 26% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-names-new-permanent-cfo-amid-warner-bros-acquisition-attempts/cmULschR47E">Paramount Names New Permanent CFO Amid Warner Bros Acquisition Attempts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Abbvie Pharma logo seen on screen in the background with pills and a medical vial with syringe, seen in this photo illustration, on 14 August 2023 in Brussels, Belgium. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly 

AbbVie already has a long acting amylin analog for the treatment of obesity in its pipeline.

Novo Nordisk A/S (NYSE:NVO) Trading Down 1.3% - Here's Why

Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.3% - Time to Sell...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Novo Nordisk A/S

Early U.S. prescription data for the oral GLP-1 Wegovy pill shows unprecedented demand, with initial numbers surpassing expectations and fueling bullish sentiment.

Geopolitical tensions surrounding Greenland's sovereignty and potential US actions are sparking debate among investors about market impact and trade implications.

Traders believe algorithms and short sellers are manipulating the stock below the $60 resistance to shake out weak hands, rallying bulls to push for a breakout.

Frustration is mounting over perceived CEO statements that investors claim are needlessly killing momentum and destroying shareholder value.

Bulls anticipate a major breakout past the $60 resistance level, eyeing a trajectory towards $70, $80, and ultimately triple digits.

Current Price	$59.19
Prev Close	$58.91
Open	$57.79
Dividend Yield	1.37%
50-Day Moving Average	$50.34
Beta	0.74
Avg. Volume	15.9M
PE Ratio	16.61

52-Week High	$93.80
52-Week Low	$43.08
Market Capitalization	$192.42B
EPS (Annual)	$3.29
Price to Book	9.49
Revenue Per Employee	$551,951.47
Enterprise Value/EBITDA	N/A

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVONovo Nordisk A/S